First-quarter earnings reports have trickled in for the last week and a half, but will really kick into high gear on April 26 when six biotech and pharma heavy hitters all report on the same day.

 

Immunotherapies, biosimilars to dominate next week of earnings and more...

Submit a Press Release to Cafepharma

Immunotherapies, biosimilars to dominate next week of earnings

First-quarter earnings reports have trickled in for the last week and a half, but will really kick into high gear on April 26 when six biotech and pharma heavy hitters all report on the same day.

 
FeedBlitz Top Slot
powered byad choices

      
 
 
 

Express Scripts targets Amgen, Lilly migraine drugs in pricing shift

The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc, Eli Lilly and Co and other makers of new migraine medicines to try and fix it.

      
 
 
 

Mylan cuts workforce at West Virginia plant by 15%

Mylan N.V. on April 20 released more than 400 workers from its Morgantown, West Virginia plant, most of whom were production employees. 

      
 
 
 

Lilly’s strong Q1 cushions the blow of FDA thumbs-down on high-dose baricitinib

It's been a good news-bad news 24 hours for Eli Lilly. Its closely watched RA prospect baricitinib didn't exactly sail through Monday's FDA committee meeting. But Tuesday morning, Lilly rolled out Q1 results that beat sales and earnings expectations. Upshot? Analysts are still worried about a baricitinib approval. 

 
FeedBlitz Top Slot
powered byad choices

      
 
 
 

Takeda reaches preliminary deal to buy Shire for close to $65B

Takeda has upped its offer to buy Shire $SHPG for a mix of stock and cash worth close to $65 billion, which is good enough for the Lexington, MA-based biotech to extend the deadline on their talks to May 8 after determining they were close to finalizing a pact.

      
 
 
 


 

Contact Us

Submit a Press Release to Cafepharma

Past Issues

Unsubscribe